Showing 478 news articles about New & experimental hepatitis C treatment

Filters Content type: Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Incivek Rash Reports: What HIV/Hepatitis C-Coinfected People Need to Know

Editor's pick
The Body
18 May 2012
New & experimental hepatitis C treatment

Achillion's hepatitis C drug gets FDA fast track

Editor's pick
Reuters
16 May 2012
New & experimental hepatitis C treatment

New Drugs Require New Terms for HCV Virologic Response

Editor's pick
Medscape (requires registration)
9 May 2012
New & experimental hepatitis C treatment

Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy

Editor's pick
MarketWatch (press release)
8 May 2012
New & experimental hepatitis C treatment

Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix

Editor's pick
The Street
8 May 2012
Pharmaceutical industry

Gilead Sciences 1Q profit down on Pharmasset costs

Editor's pick
CBS News
27 April 2012
New & experimental hepatitis C treatment

US: do not mix Merck hepatitis pill with HIV drugs

Editor's pick
Reuters
27 April 2012
New & experimental hepatitis C treatment

NICE publishes final guidance on two new drugs for chronic hepatitis C

Editor's pick
NICE press release
25 April 2012
New & experimental hepatitis C treatment

Telaprevir May Cause Severe Cutaneous Eruptions

Editor's pick
Medscape (requires free registration)
24 April 2012
New & experimental hepatitis C treatment

Grading Hep C Stocks Exiting EASL - The future of hepatitis C therapy belongs to interferon-free regimens

Editor's pick
The Street
23 April 2012
New & experimental hepatitis C treatment

Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C

Editor's pick
Achillion (press release)
23 April 2012
New & experimental hepatitis C treatment

Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C

Editor's pick
Achillion (press release)
23 April 2012
New & experimental hepatitis C treatment

J&J Open to Expanding Hepatitis C Collaboration With Vertex

Editor's pick
HCV New Drugs Research
20 April 2012
New & experimental hepatitis C treatment

Pancreatitis Forces Halt to HCV Drug Trial

Editor's pick
MedPage Today
20 April 2012
New & experimental hepatitis C treatment

Janssen Creates new Division to Launch TMC435 and Help Conquer Hepatitis C in EMEA

Editor's pick
Janssen press release
20 April 2012
New & experimental hepatitis C treatment

No Relevant Interactions Between Telaprevir and Two Newest Nonnucleosides Rilpivirine & Etravirine

Editor's pick
NATAP
20 April 2012
New & experimental hepatitis C treatment

Investigational Compound Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Flu-Like and Musculoskeletal Symptoms in Phase IIb Study in Treatment-Naive Genotype 2 or 3 Hepatitis C Patients

Editor's pick
BMS press release
20 April 2012
New & experimental hepatitis C treatment

Gilead’s Experimental Hepatitis C Drug Cured 88% Post-Therapy

Editor's pick
Bloomberg
20 April 2012
New & experimental hepatitis C treatment

Boehringer Ingelheim Hepatitis C Drugs Cured 82% in Trial

Editor's pick
Bloomberg
20 April 2012
New & experimental hepatitis C treatment

Medivir Hep C Drug Cures 80% of Patients Post-Treatment

Editor's pick
Bloomberg BusinessWeek
20 April 2012
New & experimental hepatitis C treatment

Gilead, Bristol hepatitis C trial data impresses

Editor's pick
Reuters
20 April 2012
New & experimental hepatitis C treatment

Gilead, Bristol-Myers Squibb Put Profits Ahead of Best Care for Hep C Patients

Editor's pick
The Street
20 April 2012
New & experimental hepatitis C treatment

EASL-Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy

Editor's pick
HCV New Drugs Research
19 April 2012
New & experimental hepatitis C treatment

EASL-Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C-ABT-450/r, plus ABT-333 and ribavirin

Editor's pick
HCV New Drugs Research
19 April 2012